Last Updated: Apr 08, 2022

Americans 50 and above age group can have a second COVID-19 vaccine when it has been a minimum of four months since their last vaccination. The second booster vaccine gives a better chance of protection for those most at risk of a coronavirus rebound.

The Food and Drug Administration (FDA) approved an additional dosage of the Moderna or Pfizer vaccine for 50 and above and some younger patients with highly impaired immune systems.

Later, the Centers for Disease Control and Prevention (CDC) advised the extra shot as an option but did not urge people who were eligible to have it right soon. As a result of this decision, millions more Americans will benefit from the additional boost.

CDC’s director Dr. Rochelle Walensky stated that it was particularly crucial for older Americans- who are 50 and above who suffer from chronic diseases like diabetes, heart disease; others must think about the second COVID-19 booster shot. He added that people aged 50 and above would get more benefits from the second booster dose.

According to Dr. Peter Marks, FDA vaccine chief, there is evidence to suggest that protection is declining, especially in high-risk groups, and for these groups, a booster “will aid in saving a life.”

Two doses of COVID-19 vaccine plus booster shots still provide strong protection against serious illnesses and even death in the winter swarm of the super-contagious Omicron variant. Despite the focus on who should receive a fourth dose of the Moderna or Pfizer Company vaccines, only about half of Americans eligible for a third shot have received one — despite the government’s encouragement.

The trend toward extra boosters comes at a moment of great uncertainty, with little evidence to show how much benefit an additional dose could offer right now. The number of COVID-19 infections cases in the United States has decreased to low levels. However, all vaccines are less effective against newer omicron variants than earlier versions of the coronavirus — and health officials are continuously monitoring an omicron sibling that is creating alarming increases in infections in other countries around the globe.

The Moderna Company requested a second booster dose for all adults over 50 “to offer flexibility” so that the government can determine who requires one. However, the Pfizer Company requested the FDA to allow the fourth shot only for people aged 65 and more.

The U.S. Food and Drug Administration stated that regulators had set the age limit at 50 because chronic illnesses that increase the risks of COVID-19 are more prevalent.

Until now, The U.S. Food and Drug Administration permitted an extra dose of the vaccine for people with compromised immune systems younger than 12.

According to Peter Marks, vaccines have a tough time stimulating weakened immune systems, and their protection tends to wane sooner. Tuesday’s decision gives them to get another booster shot-a fifth dose. Only the Pfizer Company vaccine is suitable for children under 12. The Moderna Company vaccine is only suitable for adults.

What about those people who received a single-dose shot from Johnson & Johnson? They were already eligible for one type of booster. The Center of Disease Control and Protection stated that around the 1.3 million people who received the second shot of J&J Company can now choose between Pfizer or Moderna for a third dose. The CDC advises boosters are only necessary for the more than 4 million people who received Moderna or Pfizer as their second shot if they meet the latest criteria: severely weakened immune system or at least 50 or more years old.

  1. John Wherry, the immunologist at the University of Pennsylvania, claims, “There may be a cause to top off the tanks a little bit” for older people and those suffering from different health issues.

While he advises older relatives and friends to adhere to the guidelines and follow the advice, the 50-year old E. John Wherry -fit, healthy, vaccinated and boosted – does not think of having a 4th shot immediately. The protection against serious illness remains solid, “I will wait until it becomes apparent that there is an urgent need.”

While the protection against milder illnesses gradually diminishes, the immune system develops several layers of defense, and one that can ward off fatal diseases and even death is holding up.

In the U.S. Omicron wave, two doses were around 80% effective against the requirement for death or ventilator. The lowest effectiveness of the COVID-19 vaccine was nearly 74% effective in patients with an immune system disorder who had not received the third dose.

U.S. officials looked at Israel and provided the fourth dose to people ages 60 and over during the omicron spike to assess an additional boost. According to FDA, there were no fresh safety concerns after the study of 700,000 fourth doses given.

Initial data published on the web last week suggested a benefit: Israeli researchers counted 92 deaths among the over 328,000 people who received the additional shot, as against 232 deaths in 234,000 people who did not receive the 4th dose.

It is unclear how long any additional benefit from another booster would last and thus when to obtain it.

“The ‘when’ is the toughest part. Ideally, we should time booster shots right before surges, but we don’t always know when that will be,” stated a vaccine specialist at the Johns Hopkins Bloomberg School of Public Health, Dr. William Moss.

According to E. John Wherry, “If you receive one of the boosters too close together, there is no harm, but you are not likely to benefit from it.”

The most recent booster may never be the last. Next week, the government will have an open meeting to discuss whether everyone will eventually require the fourth dose, which could be the vaccine initially given in the fall or an updated shot.

Even if more-risk United States People get boosted now, Marks believes they may require another dose later in the fall if regulators decide to alter the vaccination.

In this attempt, people are being studied with omicron-targeted doses alone or in combination with the original vaccine. The National Institutes of Health (NIH) has conducted research on monkeys and discovered that utilizing a booster that targets omicron has “no substantial benefit.”